Multimodal Assesment of Alzheimer Patients

NCT ID: NCT06448403

Last Updated: 2025-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2030-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).

The main questions the study aims to answer are:

1. What findings can be used to earlier detect patients that will develop Alzheimers?
2. Which differences are seen between healthy and cognitively impaired patients?
3. Which differences are seen between patients with Alzheimers disease?

Participants will undergo:

* Cognitive tests
* Magnetic resonance imaging (MRI)
* Electroencephalography (EEG)
* Blood sample collection
* Fecal sample collection
* A randomized group will undergo polysomnography analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The projects aims to map brain changes in patients with mild cognitive impairment (MCI) and Alzheimer's Disease (AD) by combining different assesment modalities.

In the MRI, researchers will get the opportunity to analyse both structural and functional brain changes. In the EEG, changes in elctrical activites will be measured. The blood samples allow researchers to analyse specific dementia and inflammation proteins, while fecal speciments can be used to assess bacterial composition. Additionally, the cognitive testing allow to assess the specific part of cognitive function which is affected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment Alzheimer Disease, Late Onset Cognitive Impairment Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MCI

Recruitment according to relevant clinical assessment and ICD-criterias.

MRI Scanning

Intervention Type DEVICE

MRI scanning with volumetric, resting and activity-based sequences.

64-channel EEG

Intervention Type DEVICE

EEG to quantifiy electric activity.

Polysomnography

Intervention Type DEVICE

A randomized group will undergo polysomnography.

Blood samples

Intervention Type BIOLOGICAL

Analysis of specific blood biomarkers.

Fecal samples

Intervention Type BIOLOGICAL

Analysis of bacterial composition.

Cognitive tests

Intervention Type BEHAVIORAL

Interview-based cognitive tests for assesment of cognitive levels.

Mild AD

Recruitment according to relevant clinical assessment and ICD-criterias.

MRI Scanning

Intervention Type DEVICE

MRI scanning with volumetric, resting and activity-based sequences.

64-channel EEG

Intervention Type DEVICE

EEG to quantifiy electric activity.

Polysomnography

Intervention Type DEVICE

A randomized group will undergo polysomnography.

Blood samples

Intervention Type BIOLOGICAL

Analysis of specific blood biomarkers.

Fecal samples

Intervention Type BIOLOGICAL

Analysis of bacterial composition.

Cognitive tests

Intervention Type BEHAVIORAL

Interview-based cognitive tests for assesment of cognitive levels.

Control

Equivalent number of research participants as in the MCI and mild AD group.

MRI Scanning

Intervention Type DEVICE

MRI scanning with volumetric, resting and activity-based sequences.

64-channel EEG

Intervention Type DEVICE

EEG to quantifiy electric activity.

Polysomnography

Intervention Type DEVICE

A randomized group will undergo polysomnography.

Blood samples

Intervention Type BIOLOGICAL

Analysis of specific blood biomarkers.

Fecal samples

Intervention Type BIOLOGICAL

Analysis of bacterial composition.

Cognitive tests

Intervention Type BEHAVIORAL

Interview-based cognitive tests for assesment of cognitive levels.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI Scanning

MRI scanning with volumetric, resting and activity-based sequences.

Intervention Type DEVICE

64-channel EEG

EEG to quantifiy electric activity.

Intervention Type DEVICE

Polysomnography

A randomized group will undergo polysomnography.

Intervention Type DEVICE

Blood samples

Analysis of specific blood biomarkers.

Intervention Type BIOLOGICAL

Fecal samples

Analysis of bacterial composition.

Intervention Type BIOLOGICAL

Cognitive tests

Interview-based cognitive tests for assesment of cognitive levels.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MCI and AD according to relevant ICD-criterias.
* Control cohort is age and gender matched with other cohorts.

Exclusion Criteria

* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)
* AD diagnosis before the age of 65 (Early-onset AD).
* Brain tumor
* Traumtic head injury
* Earlier neurosurgery
* Other neyrodegenerative diseases (i.e Parkinson and ALS)
* Diseases related to inflammation and auto-immunity (i.e MS)
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Norwegian University of Science and Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Axel Sandvig, Prof., MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Norwegian University of Science and Technology (NTNU) & St. Olavs Hospital, Trondheim University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU)

Trondheim, Trønderlag, Norway

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Norway

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Axel Sandvig, Prof., MD, PhD

Role: CONTACT

72 57 56 20

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

626476

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cohort Study on Cognitive Decline in Elderly
NCT07093892 NOT_YET_RECRUITING